4-1BB

PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody
Helena Escuin-Ordinas, Mark W Elliott, Mohammad Atefi, Michelle Lee, Charles Ng, Liu Wei, Begoña Comin-Anduix, Encarnacion Montecino-Rodriguez, Earl Avramis, Caius Radu, Leslie L Sharp, Antoni Ribas

Journal for ImmunoTherapy of Cancer Dec 2013, 1 (1) 14; DOI: 10.1186/2051-1426-1-14
CART cells are prone to Fas- and DR5-mediated cell death
Benjamin O. Tschumi, Nina Dumauthioz, Bastien Marti, Lianjun Zhang, Pascal Schneider, Jean-Pierre Mach, Pedro Romero, Alena Donda

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 71; DOI: 10.1186/s40425-018-0385-z
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors
Ezra E. W. Cohen, Michael J. Pishvaian, Dale R. Shepard, Ding Wang, Jared Weiss, Melissa L. Johnson, Christine H. Chung, Ying Chen, Bo Huang, Craig B. Davis, Francesca Toffalorio, Aron Thall, Steven F. Powell

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 342; DOI: 10.1186/s40425-019-0815-6
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
David A Schaer, Daniel Hirschhorn-Cymerman, Jedd D Wolchok

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 7; DOI: 10.1186/2051-1426-2-7

Main menu